In the News
Mobius Care Receives Funding from Crohn’s & Colitis Foundation to Advance AI-Powered Precision Medicine for Inflammatory Bowel Disease (IBD)
Mobius Care, a Cleveland Clinic-founded company that is pioneering a new approach to precision medicine for patients with Inflammatory Bowel Disease (IBD), today announced it has received funding from the Crohn’s & Colitis Foundation. The Foundation is a non-profit organization committed to finding cures for Crohn’s disease and ulcerative colitis.
Mobius Care presented groundbreaking research at the 2nd Precision Medicine in Inflammatory Bowel Disease Summit
Dr. Thaddeus Stappenbeck, the company's founder, shared insights on Mobius Care's innovative precision medicine approach for IBD treatment. The summit provided valuable opportunities for collaboration with industry leaders and reinforced our commitment to transforming IBD treatment through precision medicine.
Publications
Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn’s Disease
Therapeutic efficacy of biologics has remained at about 50% for 2 decades. In Crohn’s disease (CD) patients, we examined the predictive value of an epithelial cell biomarker, ileal microvillar length (MVL), for clinical response to ustekinumab (UST) and vedolizumab (VDZ) and its relationship to another biomarker, intestinal epithelial cell (IEC) pyroptosis, with respect to response to VDZ.
Abnormal Small Intestinal Epithelial Microvilli in Patients With Crohn’s Disease
Crohn disease (CD) presents as chronic and often progressive intestinal inflammation, but the contributing pathogenic mechanisms are unclear. We aimed to identify alterations in intestinal cells that could contribute to the chronic and progressive course of CD.
